Physician profile
Lance B Slaymaker
NPI 1336116185
$1,939.74
in general payments reported to CMS, 2019-2025
26 companies · $296 in 2025
The $296 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $25.42 · 2021: $285 · 2022: $436 · 2023: $430 · 2024: $312 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,038.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $400.43 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $179.83 | 2021-2025 | Qelbree, Qelbree |
| Cranial Technologies, INC | $166.08 | 2019-2025 | Doc Band |
| Tris Pharma INC | $164.79 | 2021-2023 | Dyanavel Xr |
| Sanofi Pasteur INC. | $135.12 | 2021-2025 | |
| Pfizer INC. | $127.13 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $126.07 | 2020-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Neos Therapeutics, Lp | $76.79 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $71.05 | 2022-2023 | Flumist Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $63.33 | 2021 | |
| Kaleo, INC. | $57.12 | 2022-2024 | Auvi-Q |
| Collegium Pharmaceutical, INC. | $44.73 | 2025 | Jornay Pm |
| Seqirus USA INC | $42.39 | 2022-2025 | Flucelvax |
| Hologic Sales and Service, LLC | $39.56 | 2022-2025 | Aptima, Thinprep 2000 Processor |
| Glaxosmithkline, LLC. | $37.41 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $31.90 | 2024 | |
| Genentech USA, INC. | $25.24 | 2021-2022 | |
| Sobi, INC | $22.39 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $21.33 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.07 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.74 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.22 | 2025 | Relexxii |
| Noven Therapeutics, LLC | $15.17 | 2025 | Xelstrym |
| Teva Pharmaceuticals USA, INC. | $15.05 | 2021 | |
| Phadia US INC. | $14.16 | 2024 | Immunocap |
| Shire North American Group INC | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Slaymaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.